Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HU Prevent
NCT01389024Phase 2Completed
- Sponsor
- Johns Hopkins University
- Start
- Aug 2012
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in sickle cell disease (SCD) comparing Hydroxyurea with Placebo (2 arms). Primary endpoint: Number of Randomized Participants With Central Nervous System Complications at 3 years. Started Aug 2012; status: completed.
02
Drugs
hydroxyurea
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT01389024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01389024.